市場調查報告書
商品編碼
893770

核酸適體的全球市場

Aptamers

出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 342 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球核酸適體的市場調查,市場定義和概要,主要趨勢、市場成長的各種影響因素分析,企業及企業間的配合措施,競爭環境與市場佔有率,世界及各地區、國家的市場規模的變化與預測,各類型 (DNA、RNA、XNA)、用途 (診斷、治療、R&D)、技術 (SELEX、其他) 的明細,主要企業簡介等資訊。

第1章 調查手法

第2章 摘要整理

  • 市場概要
    • 核酸適體:概要
    • 進步、發現
    • 全球企業佔有率
      • 企業佔有率方案:成果、預測
    • 企業佔有率成果、預測:各類型
      • DNA
      • RNA
      • XNA
    • 企業佔有率成果、預測:各技術
      • SELEX
  • 主要企業
  • 市場趨勢、成長推動因素
  • 全球市場的展望

第3章 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
    • 法國
    • 德國
    • 義大利
    • 英國
    • 西班牙
    • 俄羅斯
    • 其他
  • 亞太地區
    • 澳洲
    • 印度
    • 韓國
    • 其他
  • 南美
    • 阿根廷
    • 巴西
    • 墨西哥
    • 其他
  • 中東
    • 伊朗
    • 以色列
    • 沙烏地阿拉伯
    • UAE
    • 其他
  • 非洲

第4章 競爭企業

  • AM BIOTECHNOLOGIES, LLC
  • APTAGEN, LLC
  • APTAMER GROUP
  • APTAMER SCIENCES INC.
  • APTUS BIOTECH
  • BASE PAIR BIOTECHNOLOGIES, INC.
  • NEOVENTURES BIOTECHNOLOGY INC.
  • SOMALOGIC
  • TRILINK BIOTECHNOLOGIES
  • VIVONICS

第5章 調查資料

目錄
Product Code: MCP10352

Abstract:

Global Aptamers Market to Reach $1.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Aptamers estimated at US$460.6 Million in the year 2020, is projected to reach a revised size of US$1.4 Billion by 2027, growing at a CAGR of 16.8% over the analysis period 2020-2027. DNA, one of the segments analyzed in the report, is projected to record a 16.3% CAGR and reach US$744.4 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the RNA segment is readjusted to a revised 16.3% CAGR for the next 7-year period.

The U.S. Market is Estimated at $124 Million, While China is Forecast to Grow at 21.6% CAGR

The Aptamers market in the U.S. is estimated at US$124 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$317.3 Million by the year 2027 trailing a CAGR of 21.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.2% and 14.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.2% CAGR.

XNA Segment to Record 19.5% CAGR

In the global XNA segment, USA, Canada, Japan, China and Europe will drive the 18.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$49.1 Million in the year 2020 will reach a projected size of US$159.9 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$212.9 Million by the year 2027, while Latin America will expand at a 21.4% CAGR through the analysis period.

Select Competitors (Total 46 Featured) -

  • AM Biotechnologies, LLC
  • Aptagen, LLC
  • Aptamer Group
  • Aptamer Sciences Inc.
  • Aptus Biotech
  • Base Pair Biotechnologies, Inc.
  • NeoVentures Biotechnology Inc.
  • SomaLogic, Inc.
  • TriLink BioTechnologies, LLC.
  • Vivonics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • An Overview Aptamers
    • Aptamers - Advances and Discoveries
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Aptamers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for DNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for DNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for RNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for RNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 7: World Current & Future Analysis for XNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for XNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 9: World Current & Future Analysis for SELEX by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for SELEX by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 11: World Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 12: World 7-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 14: World 7-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 15: World Current & Future Analysis for Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 16: World 7-Year Perspective for Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 17: World Current & Future Analysis for R&D by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 18: World 7-Year Perspective for R&D by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 20: World 7-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 21: World Current & Future Analysis for Biotechnology & Pharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 22: World 7-Year Perspective for Biotechnology & Pharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 23: World Current & Future Analysis for CRO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 24: World 7-Year Perspective for CRO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 26: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 27: USA Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 28: USA 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 29: USA Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 30: USA 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 31: USA Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 33: USA Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 34: USA 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • CANADA
    • TABLE 35: Canada Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 36: Canada 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 37: Canada Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Canada 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 39: Canada Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 40: Canada 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 41: Canada Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 42: Canada 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • JAPAN
    • TABLE 43: Japan Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Japan 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 45: Japan Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 46: Japan 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 47: Japan Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 48: Japan 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 49: Japan Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • CHINA
    • TABLE 51: China Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 52: China 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 53: China Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 54: China 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 55: China Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 57: China Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 58: China 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • EUROPE
    • TABLE 59: Europe Current & Future Analysis for Aptamers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 60: Europe 7-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 61: Europe Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Europe 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 63: Europe Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 64: Europe 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 65: Europe Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 66: Europe 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 67: Europe Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • FRANCE
    • TABLE 69: France Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 70: France 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 71: France Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 72: France 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 73: France Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 74: France 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 75: France Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 76: France 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • GERMANY
    • TABLE 77: Germany Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 78: Germany 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 79: Germany Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 80: Germany 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 81: Germany Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 82: Germany 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 83: Germany Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 84: Germany 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • ITALY
    • TABLE 85: Italy Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Italy 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 87: Italy Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 88: Italy 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 89: Italy Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 90: Italy 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 91: Italy Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Italy 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 93: UK Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 94: UK 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 95: UK Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 96: UK 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 97: UK Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 98: UK 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 99: UK Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 100: UK 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • SPAIN
    • TABLE 101: Spain Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 102: Spain 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 103: Spain Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Spain 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 105: Spain Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 106: Spain 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 107: Spain Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 108: Spain 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • RUSSIA
    • TABLE 109: Russia Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Russia 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 111: Russia Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 112: Russia 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 113: Russia Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 114: Russia 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 115: Russia Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Russia 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 117: Rest of Europe Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 118: Rest of Europe 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 119: Rest of Europe Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 120: Rest of Europe 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 121: Rest of Europe Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of Europe 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 123: Rest of Europe Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 124: Rest of Europe 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 125: Asia-Pacific Current & Future Analysis for Aptamers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 126: Asia-Pacific 7-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020 & 2027
    • TABLE 127: Asia-Pacific Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Asia-Pacific 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 129: Asia-Pacific Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 130: Asia-Pacific 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 131: Asia-Pacific Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 132: Asia-Pacific 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 133: Asia-Pacific Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 134: Asia-Pacific 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • AUSTRALIA
    • TABLE 135: Australia Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 136: Australia 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 137: Australia Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 138: Australia 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 139: Australia Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 140: Australia 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 141: Australia Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 142: Australia 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • INDIA
    • TABLE 143: India Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 144: India 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 145: India Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 146: India 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 147: India Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 148: India 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 149: India Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 150: India 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • SOUTH KOREA
    • TABLE 151: South Korea Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 152: South Korea 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 153: South Korea Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 154: South Korea 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 155: South Korea Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 156: South Korea 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 157: South Korea Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 158: South Korea 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 159: Rest of Asia-Pacific Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 160: Rest of Asia-Pacific 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 161: Rest of Asia-Pacific Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 162: Rest of Asia-Pacific 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 163: Rest of Asia-Pacific Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 164: Rest of Asia-Pacific 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 165: Rest of Asia-Pacific Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 166: Rest of Asia-Pacific 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • LATIN AMERICA
    • TABLE 167: Latin America Current & Future Analysis for Aptamers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 168: Latin America 7-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020 & 2027
    • TABLE 169: Latin America Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 170: Latin America 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 171: Latin America Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 172: Latin America 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 173: Latin America Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 174: Latin America 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 175: Latin America Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 176: Latin America 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • ARGENTINA
    • TABLE 177: Argentina Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 178: Argentina 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 179: Argentina Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 180: Argentina 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 181: Argentina Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 182: Argentina 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 183: Argentina Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 184: Argentina 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • BRAZIL
    • TABLE 185: Brazil Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 186: Brazil 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 187: Brazil Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 188: Brazil 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 189: Brazil Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 190: Brazil 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 191: Brazil Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 192: Brazil 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • MEXICO
    • TABLE 193: Mexico Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 194: Mexico 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 195: Mexico Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 196: Mexico 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 197: Mexico Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 198: Mexico 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 199: Mexico Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 200: Mexico 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 201: Rest of Latin America Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 202: Rest of Latin America 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 203: Rest of Latin America Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 204: Rest of Latin America 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 205: Rest of Latin America Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 206: Rest of Latin America 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 207: Rest of Latin America Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 208: Rest of Latin America 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • MIDDLE EAST
    • TABLE 209: Middle East Current & Future Analysis for Aptamers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
    • TABLE 210: Middle East 7-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020 & 2027
    • TABLE 211: Middle East Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 212: Middle East 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 213: Middle East Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 214: Middle East 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 215: Middle East Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 216: Middle East 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 217: Middle East Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 218: Middle East 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • IRAN
    • TABLE 219: Iran Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 220: Iran 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 221: Iran Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 222: Iran 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 223: Iran Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 224: Iran 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 225: Iran Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 226: Iran 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • ISRAEL
    • TABLE 227: Israel Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 228: Israel 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 229: Israel Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 230: Israel 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 231: Israel Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 232: Israel 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 233: Israel Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 234: Israel 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • SAUDI ARABIA
    • TABLE 235: Saudi Arabia Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 236: Saudi Arabia 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 237: Saudi Arabia Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 238: Saudi Arabia 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 239: Saudi Arabia Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 240: Saudi Arabia 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 241: Saudi Arabia Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 242: Saudi Arabia 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 243: UAE Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 244: UAE 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 245: UAE Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 246: UAE 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 247: UAE Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 248: UAE 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 249: UAE Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 250: UAE 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 251: Rest of Middle East Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 252: Rest of Middle East 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 253: Rest of Middle East Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 254: Rest of Middle East 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 255: Rest of Middle East Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 256: Rest of Middle East 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 257: Rest of Middle East Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 258: Rest of Middle East 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027
  • AFRICA
    • TABLE 259: Africa Current & Future Analysis for Aptamers by Type - DNA, RNA and XNA - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 260: Africa 7-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA, RNA and XNA for the Years 2020 & 2027
    • TABLE 261: Africa Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 262: Africa 7-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2020 & 2027
    • TABLE 263: Africa Current & Future Analysis for Aptamers by Application - Diagnostics, Therapeutics and R&D - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 264: Africa 7-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Diagnostics, Therapeutics and R&D for the Years 2020 & 2027
    • TABLE 265: Africa Current & Future Analysis for Aptamers by End-Use - Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
    • TABLE 266: Africa 7-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Academic Research Institutes, Biotechnology & Pharmaceutical Companies, CRO and Other End-Uses for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 46